chenodeoxycholic acid has been researched along with Neurodegenerative Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, TL; Mayence, A; Vanden Eynde, JJ | 1 |
| Fardghassemi, Y; Maios, C; Parker, JA | 1 |
| Amador, MDM; Debs, R; Degos, B; Lamari, F; Masingue, M; Mochel, F; Perlbarg, V; Roze, E | 1 |
1 review(s) available for chenodeoxycholic acid and Neurodegenerative Diseases
| Article | Year |
|---|---|
Some non-conventional biomolecular targets for diamidines. A short survey.
Topics: Amidines; Animals; Diabetes Mellitus, Type 2; DNA; Enzymes; Humans; Hypertension; Ion Channels; Myotonic Dystrophy; Neoplasms; Neurodegenerative Diseases; Proteins; RNA; Thrombosis | 2014 |
2 other study(ies) available for chenodeoxycholic acid and Neurodegenerative Diseases
| Article | Year |
|---|---|
Small Molecule Rescue of ATXN3 Toxicity in C. elegans via TFEB/HLH-30.
Topics: Animals; Animals, Genetically Modified; Ataxin-3; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Basic Helix-Loop-Helix Transcription Factors; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Chenodeoxycholic Acid; Drug Evaluation, Preclinical; Longevity; Neurodegenerative Diseases; Phenylbutyrates; Sulfaphenazole | 2021 |
Treatment with chenodeoxycholic acid in cerebrotendinous xanthomatosis: clinical, neurophysiological, and quantitative brain structural outcomes.
Topics: Adolescent; Adult; Brain; Chenodeoxycholic Acid; Child; Cholestanol; Diarrhea; Electromyography; Female; Humans; Intellectual Disability; Magnetic Resonance Imaging; Male; Middle Aged; Neurodegenerative Diseases; Neurologic Examination; Retrospective Studies; Severity of Illness Index; Xanthomatosis, Cerebrotendinous; Young Adult | 2018 |